ProMIS Neurosciences, Inc.
NASDAQ:PMNBiotechnology
-$0.02 today
- Market cap
- $99.36M
- Beta
- -0.22
- P/E (TTM)
- -0.6
- EPS (TTM)
- -$4.62
Volume 0.13M
Average 0.07M
PMN Weighted Avg Shares
Average number of basic shares outstanding during the period, used to calculate basic EPS.
ProMIS Neurosciences, Inc.NASDAQ: PMN
Weighted Avg Shares · Q2 FY2026 · quarter ended Jun 2026
Weighted avg shares growth accelerates
Q2 FY2026 weighted avg shares of 9.14M shares rose 555.8% year over year, ahead of the +249.7% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 40.1% from the prior quarter. Over 3 fiscal years it compounded at +80.2% a year.
Context
- Weighted avg shares increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +555.8% holds above the trailing-twelve-month pace of +249.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Weighted Avg Shares history
Shares · from the income statement
- Latest · FY2025
- 1.76M USD
- Year-over-year change
- +69.4%
| Period | Period end | Weighted Avg Shares | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.76M | +69.4% |
| FY2024 | 2024-12-31 | 1.04M | +110.9% |
| FY2023 | 2023-12-31 | 491.71K | — |
| FY2022 | 2022-12-31 | 300.1K | +29.7% |
| FY2021 | 2021-12-31 | 231.42K | — |
Weighted Avg Shares vs competitors
How PMN compares with its peers on the latest reported figures
- PMN's LTM Jun 2026 weighted avg shares of 4.71M shares is the lowest of the 4 companies compared; the peer median is 7.76M shares.
- Its year-over-year change of +249.7% is the highest of 3, against a peer median of +52.5%.
- Over three fiscal years its annual growth of +80.2% compares with a peer median of +7.9%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | 43.04M | +3.9% | +2.0% | |
| LTM Jun 2024 | 7.76M | — | +7.9% | |
| LTM Mar 2026 | 7.58M | +101.1% | +39.4% | |
| LTM Jun 2026 | 4.71M | +249.7% | +80.2% | |
| Peer median (excluding PMN) | 7.76M | +52.5% | +7.9% | |
Competitors are the stored peer set for PMN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 · CAD | FY2022 Dec 2022 · CAD | FY2023 Dec 2023 · USD | FY2024 Dec 2024 · USD | FY2025 Dec 2025 · USD |
|---|---|---|---|---|---|
| Revenue | 16.68K | 0 | 0 | 0 | 0 |
| Cost of Revenue | 5.85M | 0 | 10.44M | 0 | 0 |
| Gross Profit | (5.84M) | 0 | (10.44M) | 0 | 0 |
| Gross Margin | -35031.9% | — | — | — | — |
| Research & Development | 4.95M | 16.09B | 7.88M | 10.64M | 33.38M |
| Selling, General & Admin | 3.31M | 7.29B | 6.38M | 6.19M | 6.79M |
| Operating Expenses | 4.63M | 23.38B | 8.45M | 16.83M | 40.17M |
| Depreciation & Amortization | 45.83K | 0 | 28.04K | 0 | 0 |
| EBITDA | (9.33M) | (17.78B) | (17.81M) | 2.86M | (39.72M) |
| EBITDA Margin | -55923.2% | — | — | — | — |
| Operating Income | (10.57M) | (23.38B) | (18.9M) | (16.83M) | (40.17M) |
| Operating Margin | -63350.5% | — | — | — | — |
| Interest Income | 4.73K | 0 | 0 | 0 | 0 |
| Interest Expense | 416.29K | 282.06M | 201.39K | 76.78K | 0 |
| Other Income / Expenses | (1.91M) | 5.32B | 1.39M | 19.61M | 448.16K |
| Income Before Tax | (12.48M) | (18.06B) | (17.51M) | 2.78M | (39.72M) |
| Pre-Tax Margin | -74804.2% | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (11.98M) | (18.06B) | (17.51M) | 2.78M | (39.72M) |
| Net Margin | -71819.3% | — | — | — | — |
| EPS (Basic) | (51.77) | (60.25) | (35.50) | 2.75 | (22.61) |
| EPS (Diluted) | (51.77) | (60.25) | (35.50) | 2.75 | (22.61) |
| Weighted Avg Shares | 231.42K | 300.1K | 491.71K | 1.04M | 1.76M |
| Weighted Avg Shares (Diluted) | 231.43K | 300.1K | 491.71K | 1.06M | 1.76M |
ProMIS Neurosciences, Inc.
NASDAQ:PMN
Intrinsic Alpha fair value
Locked
Current Price
$11.08
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.